147 related articles for article (PubMed ID: 31722207)
1. The GTPase Domain of MX2 Interacts with the HIV-1 Capsid, Enabling Its Short Isoform to Moderate Antiviral Restriction.
Betancor G; Dicks MDJ; Jimenez-Guardeño JM; Ali NH; Apolonia L; Malim MH
Cell Rep; 2019 Nov; 29(7):1923-1933.e3. PubMed ID: 31722207
[TBL] [Abstract][Full Text] [Related]
2. Pro-515 of the dynamin-like GTPase MxB contributes to HIV-1 inhibition by regulating MxB oligomerization and binding to HIV-1 capsid.
Xu F; Zhao F; Zhao X; Zhang D; Liu X; Hu S; Mei S; Fan Z; Huang Y; Sun H; Wei L; Wu C; Li Q; Wang J; Cen S; Liang C; Guo F
J Biol Chem; 2020 May; 295(19):6447-6456. PubMed ID: 32217692
[TBL] [Abstract][Full Text] [Related]
3. Restriction of HIV-1 Requires the N-Terminal Region of MxB as a Capsid-Binding Motif but Not as a Nuclear Localization Signal.
Schulte B; Buffone C; Opp S; Di Nunzio F; De Souza Aranha Vieira DA; Brandariz-Nuñez A; Diaz-Griffero F
J Virol; 2015 Aug; 89(16):8599-610. PubMed ID: 26063425
[TBL] [Abstract][Full Text] [Related]
4. GTPase Activity of MxB Contributes to Its Nuclear Location, Interaction with Nucleoporins and Anti-HIV-1 Activity.
Xie L; Ju Z; Zhong C; Wu Y; Zan Y; Hou W; Feng Y
Virol Sin; 2021 Feb; 36(1):85-94. PubMed ID: 32632818
[TBL] [Abstract][Full Text] [Related]
5. MX2 Viral Substrate Breadth and Inhibitory Activity Are Regulated by Protein Phosphorylation.
Betancor G; Bangham M; Jeon JK; Shah K; Lynham S; Jimenez-Guardeño JM; Malim MH
mBio; 2022 Aug; 13(4):e0171422. PubMed ID: 35880880
[TBL] [Abstract][Full Text] [Related]
6. Transfer of the amino-terminal nuclear envelope targeting domain of human MX2 converts MX1 into an HIV-1 resistance factor.
Goujon C; Moncorgé O; Bauby H; Doyle T; Barclay WS; Malim MH
J Virol; 2014 Aug; 88(16):9017-26. PubMed ID: 24899177
[TBL] [Abstract][Full Text] [Related]
7. MxB binds to the HIV-1 core and prevents the uncoating process of HIV-1.
Fricke T; White TE; Schulte B; de Souza Aranha Vieira DA; Dharan A; Campbell EM; Brandariz-Nuñez A; Diaz-Griffero F
Retrovirology; 2014 Aug; 11():68. PubMed ID: 25123063
[TBL] [Abstract][Full Text] [Related]
8. Contribution of MxB oligomerization to HIV-1 capsid binding and restriction.
Buffone C; Schulte B; Opp S; Diaz-Griffero F
J Virol; 2015 Mar; 89(6):3285-94. PubMed ID: 25568212
[TBL] [Abstract][Full Text] [Related]
9. Oligomerization Requirements for MX2-Mediated Suppression of HIV-1 Infection.
Dicks MD; Goujon C; Pollpeter D; Betancor G; Apolonia L; Bergeron JR; Malim MH
J Virol; 2016 Jan; 90(1):22-32. PubMed ID: 26446602
[TBL] [Abstract][Full Text] [Related]
10. Equine Myxovirus Resistance Protein 2 Restricts Lentiviral Replication by Blocking Nuclear Uptake of Capsid Protein.
Ji S; Na L; Ren H; Wang Y; Wang X
J Virol; 2018 Sep; 92(18):. PubMed ID: 29743377
[TBL] [Abstract][Full Text] [Related]
11. Virus specificity and nucleoporin requirements for MX2 activity are affected by GTPase function and capsid-CypA interactions.
Layish B; Goli R; Flick H; Huang SW; Zhang RZ; Kvaratskhelia M; Kane M
PLoS Pathog; 2024 Mar; 20(3):e1011830. PubMed ID: 38512975
[TBL] [Abstract][Full Text] [Related]
12. MX2-mediated innate immunity against HIV-1 is regulated by serine phosphorylation.
Betancor G; Jimenez-Guardeño JM; Lynham S; Antrobus R; Khan H; Sobala A; Dicks MDJ; Malim MH
Nat Microbiol; 2021 Aug; 6(8):1031-1042. PubMed ID: 34282309
[TBL] [Abstract][Full Text] [Related]
13. MX2 is an interferon-induced inhibitor of HIV-1 infection.
Kane M; Yadav SS; Bitzegeio J; Kutluay SB; Zang T; Wilson SJ; Schoggins JW; Rice CM; Yamashita M; Hatziioannou T; Bieniasz PD
Nature; 2013 Oct; 502(7472):563-6. PubMed ID: 24121441
[TBL] [Abstract][Full Text] [Related]
14. MxB Restricts HIV-1 by Targeting the Tri-hexamer Interface of the Viral Capsid.
Smaga SS; Xu C; Summers BJ; Digianantonio KM; Perilla JR; Xiong Y
Structure; 2019 Aug; 27(8):1234-1245.e5. PubMed ID: 31155311
[TBL] [Abstract][Full Text] [Related]
15. Multiple components of the nuclear pore complex interact with the amino-terminus of MX2 to facilitate HIV-1 restriction.
Dicks MDJ; Betancor G; Jimenez-Guardeño JM; Pessel-Vivares L; Apolonia L; Goujon C; Malim MH
PLoS Pathog; 2018 Nov; 14(11):e1007408. PubMed ID: 30496303
[TBL] [Abstract][Full Text] [Related]
16. Host and viral determinants of Mx2 antiretroviral activity.
Busnadiego I; Kane M; Rihn SJ; Preugschas HF; Hughes J; Blanco-Melo D; Strouvelle VP; Zang TM; Willett BJ; Boutell C; Bieniasz PD; Wilson SJ
J Virol; 2014 Jul; 88(14):7738-52. PubMed ID: 24760893
[TBL] [Abstract][Full Text] [Related]
17. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection.
Goujon C; Moncorgé O; Bauby H; Doyle T; Ward CC; Schaller T; Hué S; Barclay WS; Schulz R; Malim MH
Nature; 2013 Oct; 502(7472):559-62. PubMed ID: 24048477
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the amino-terminal domain of Mx2/MxB-dependent interaction with the HIV-1 capsid.
Kong J; Xu B; Wei W; Wang X; Xie W; Yu XF
Protein Cell; 2014 Dec; 5(12):954-7. PubMed ID: 25363729
[No Abstract] [Full Text] [Related]
19. A triple-arginine motif in the amino-terminal domain and oligomerization are required for HIV-1 inhibition by human MX2.
Goujon C; Greenbury RA; Papaioannou S; Doyle T; Malim MH
J Virol; 2015 Apr; 89(8):4676-80. PubMed ID: 25673704
[TBL] [Abstract][Full Text] [Related]
20. Naturally Occurring Mutations in HIV-1 CRF01_AE Capsid Affect Viral Sensitivity to Restriction Factors.
Nakayama EE; Saito A; Sultana T; Jin Z; Nohata K; Shibata M; Hosoi M; Motomura K; Shioda T; Sangkitporn S; Loket R; Saeng-Aroon S
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):382-392. PubMed ID: 29325426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
